E. Woolf, T. Au, H. Haddix, and B. Matuszewski, Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching, Journal of Chromatography A, vol.692, issue.1-2, pp.45-52, 1995.
DOI : 10.1016/0021-9673(94)00608-C

R. Drew, S. Weller, H. Gallis, K. Walmer, J. Bartlett et al., Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus., Antimicrobial Agents and Chemotherapy, vol.33, issue.10, pp.1801-1804, 1989.
DOI : 10.1128/AAC.33.10.1801

E. Voigt, A. Wickesberg, and J. Wasmuth, First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results, HIV Medicine, vol.14, issue.17, pp.277-82, 2002.
DOI : 10.1097/00002030-200006160-00015

D. Konopnicki, D. Wit, S. Poll, B. Crommentuyn, K. Huitema et al., Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily, HIV Medicine, vol.29, issue.1, pp.1-6, 2005.
DOI : 10.1097/00002030-200210180-00019

E. Acosta, H. Wu, and S. Hammer, Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.37, issue.3, pp.1358-66, 2004.
DOI : 10.1097/00126334-200411010-00004

C. Solas, S. Basso, and I. Poizot-martin, High indinavir C is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen min, J Acquir

D. Burger, P. Hugen, and R. Aarnoutse, A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.26, issue.3, pp.218-242, 2001.
DOI : 10.1097/00126334-200103010-00003

J. Arnaiz, J. Mallolas, and D. Podzamczer, Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load, AIDS, vol.17, issue.6, pp.831-871, 2003.
DOI : 10.1097/00002030-200304110-00008

D. Burger, M. Boyd, and C. Duncombe, Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients, Journal of Antimicrobial Chemotherapy, vol.51, issue.5, pp.1231-1239, 2003.
DOI : 10.1093/jac/dkg198

X. Duval, G. Peytavin, and I. Albert, Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients, HIV Medicine, vol.14, issue.4, pp.307-320, 2004.
DOI : 10.1097/00002030-199910010-00001

J. Herman, N. Ives, M. Nelson, B. Gazzard, and P. Easterbrook, Incidence and risk factors for the development of indinavir-associated renal complications, Journal of Antimicrobial Chemotherapy, vol.48, issue.3, pp.355-60, 2001.
DOI : 10.1093/jac/48.3.355

J. Dieleman, M. Sturkenboom, and M. Jambroes, Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease Inhibitor Indinavir Sulfate<subtitle>The ATHENA Cohort</subtitle>, Archives of Internal Medicine, vol.162, issue.13, pp.1493-501, 2002.
DOI : 10.1001/archinte.162.13.1493

S. Balani, E. Woolf, and V. Hoagland, Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans, Drug Metab Dispos, vol.24, pp.1389-94, 1996.

E. Mortier, S. Toure, C. Seyler, M. Bloch, and X. Anglaret, Urinary pH in HIV-infected adults in Ivory Coast and in France, AIDS, vol.17, issue.13, pp.2003-2008, 2003.
DOI : 10.1097/00002030-200309050-00028

B. Kappelhoff, A. Huitema, and S. Sankatsing, Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.24, issue.3, pp.276-86, 2005.
DOI : 10.1067/mcp.2002.121424

J. Lin, M. Chiba, I. Chen, J. Nishime, and K. Vastag, Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence, Drug Metab Dispos, vol.24, pp.1298-306, 1996.

R. Gagnon, S. Tecimer, A. Watters, and C. Tsoukas, Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir, American Journal of Kidney Diseases, vol.36, issue.3, pp.507-522, 2000.
DOI : 10.1053/ajkd.2000.9791

M. Dworkin and P. Wan, Indinavir, Zidovudine, Lamivudine: 3-Year Follow-up, Annals of Internal Medicine, vol.134, issue.2, p.165, 2001.
DOI : 10.7326/0003-4819-134-2-200101160-00019

J. Ghosn, C. Lamotte, and H. Ait-mohand, Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients, AIDS, vol.17, issue.2, pp.209-223, 2003.
DOI : 10.1097/00002030-200301240-00011

C. Duvivier, A. Myrto, and A. Marcelin, Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals, Antivir Ther, vol.8, pp.603-612, 2003.